⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TNYA News
Tenaya Therapeutics, Inc. Common Stock
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
globenewswire.com
TNYA
Form 8-K
sec.gov
TNYA
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
TNYA
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
globenewswire.com
TNYA
Form 8-K
sec.gov
TNYA
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
globenewswire.com
ALNY
TNYA
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
globenewswire.com
TNYA
Trilogy Innovations Included in $151B Missile Defense Agency Contract
prnewswire.com
TNYA
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones
globenewswire.com
TNYA
Gene Therapies for Cardiomyopathies Market Poised for Rapid Expansion During the Forecast Period (2025-2034) with Advancements in AAV and CRISPR Platforms | DelveInsight
prnewswire.com
LXEO
TNYA
RPTX